Erasca, Inc. (ERAS) Covered Calls
Erasca, Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s pipeline is designed to shut down one of cancer’s most commonly mutated signaling cascades. Its lead candidates include ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor. Erasca targets various solid tumors, aiming to provide comprehensive treatment solutions.
You can sell covered calls on Erasca, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ERAS (prices last updated Fri 4:16 PM ET):
| Erasca, Inc. (ERAS) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 15.47 | -0.07 | 15.06 | 16.03 | 5.0M | - | 4.4 |
| Covered Calls For Erasca, Inc. (ERAS) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Mar 20 | 15 | 1.15 | 14.88 | 0.8% | 19.5% | |
| Apr 17 | 15 | 2.25 | 13.78 | 8.9% | 75.5% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Erasca, Inc. is a biotechnology firm whose mission is embedded in its name: to erase cancer. The company is dedicated to treating patients with cancers driven by the RAS/MAPK pathway, which is one of the most frequently mutated signaling pathways in human oncology. Erasca has assembled a deep, modality-agnostic pipeline that targets this pathway from multiple angles, including direct inhibitors of RAS and KRAS, as well as agents targeting upstream and downstream nodes of the signaling cascade.
The company’s lead therapeutic candidates are designed to address significant unmet needs in solid tumors such as non-small cell lung cancer, colorectal cancer, and pancreatic cancer. ERAS-0015 is a potential best-in-class pan-RAS molecular glue that aims to inhibit multiple RAS variants. Meanwhile, ERAS-4001 is an oral, potent pan-KRAS inhibitor. By utilizing combination regimens and precision medicine, Erasca seeks to overcome the resistance mechanisms that often limit the effectiveness of current single-agent treatments.
Competition
The field of RAS/MAPK targeting is highly competitive, featuring several large pharmaceutical companies and well-funded biotechnology firms. Erasca competes with companies developing similar molecular glues and KRAS inhibitors. Key competitors with active options trading on major exchanges include Amgen, Merck, and AstraZeneca. Other notable peers in the precision oncology space include Gilead Sciences and Relay Therapeutics.
Strategic Outlook and Innovation
Strategic innovation at Erasca is focused on the rapid clinical advancement of its RAS-targeting franchise to establish proof-of-concept in various solid tumor indications. The company is prioritizing clinical collaborations to evaluate its candidates in combination with other targeted therapies, such as PRMT5 inhibitors. These partnerships are intended to maximize the therapeutic potential of its pipeline while sharing the costs and risks associated with complex oncology clinical trials.
Looking forward, the company is committed to leveraging its scientific expertise to identify new "escape routes" that cancers use to bypass RAS/MAPK inhibition. By staying at the forefront of signaling pathway research, Erasca aims to develop second-generation therapies that provide more durable responses for patients. The company’s long-term strategy involves maintaining a robust balance sheet to fund these research and development efforts, ensuring a steady progression of candidates from discovery through to potential commercialization.
| Top 10 Open Interest For Mar 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | CTMX covered calls | |
| 2. | SLV covered calls | 7. | EWZ covered calls | 2. | MRVL covered calls | |
| 3. | EEM covered calls | 8. | GLD covered calls | 3. | REPL covered calls | |
| 4. | SPY covered calls | 9. | FXI covered calls | 4. | QURE covered calls | |
| 5. | IBIT covered calls | 10. | SOFI covered calls | 5. | PATH covered calls | |
Want more examples? EQX Covered Calls | ERIC Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
